A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01382992

Enrollment

150

Registered

2011-06-27

Start date

2010-06-30

Completion date

Unknown

Last updated

2011-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Keywords

Carcinoma, Non-Small-Cell Lung, erbB-1

Brief summary

EGFR mutations plays an essential role in EGFR-TKIs treatment. However, for some patients, tissue samples are not available. The purpose of this study is to determine whether blood sample is feasible for EGFR mutation detection.For late stage NSCLC, we hypothesis plasma sample is an alternative for detecting EGFR mutations.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Non-small cell lung cancer * Available plasma and pathologically confirmed tissue slices(pre-chemo and pre-radio therapy) * Informed Consent

Exclusion criteria

* N/A

Design outcomes

Primary

Measure	Time frame
To determine the consistence of EGFR mutation status in paired tissue and plasma samples	3 months

Secondary

Measure	Time frame
To determine the EGFR mutation status in Chinese NSCLC	3month

Countries

China

Outcome results